NO20085158L - Farmasoytiske blandinger av ropinirol samt deres anvendelse - Google Patents

Farmasoytiske blandinger av ropinirol samt deres anvendelse

Info

Publication number
NO20085158L
NO20085158L NO20085158A NO20085158A NO20085158L NO 20085158 L NO20085158 L NO 20085158L NO 20085158 A NO20085158 A NO 20085158A NO 20085158 A NO20085158 A NO 20085158A NO 20085158 L NO20085158 L NO 20085158L
Authority
NO
Norway
Prior art keywords
agents
compositions
ropinirole
hydroalcoholic
present
Prior art date
Application number
NO20085158A
Other languages
English (en)
Inventor
Gene Jamieson
Dario Norberto Carrara
Arnaud Grenier
Original Assignee
Jazz Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals filed Critical Jazz Pharmaceuticals
Publication of NO20085158L publication Critical patent/NO20085158L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Foreliggende oppfinnelse omfatter preparater for levering av et farmasøytisk medikament av et indolon (for eksempel ropinirol), eller et farmasøytisk akseptabelt salt derav. Preparatet kan for eksempel være en gel egnet for transdermal anvendelse. Preparatene ifølge foreliggende oppfinnelse omfatter typisk en hydro- alkoholisk konstituent, en eller flere antioksidanter og ett eller flere bufringsmidler, hvor pH i gelen vanligvis er mellom ca. pH 7 og ca. pH 9. Preparatene kan omfatte ytterligere komponenter; for eksempel kan den hydroalkoholiske konstituenten videre omfatte ytterligere løsningsmiddel/midler, antioksidant(er), medløsningsmiddel/midler, penetreringsforbedrende middel/midler, bufringsmiddel/midler og/eller geldannende middel/midler. Preparatene kan anvendes for behandling av en rekke nevrologiske lidelser.
NO20085158A 2006-06-29 2008-12-11 Farmasoytiske blandinger av ropinirol samt deres anvendelse NO20085158L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81725906P 2006-06-29 2006-06-29
PCT/US2007/014821 WO2008005240A2 (en) 2006-06-29 2007-06-26 Ropinirole-containing pharmaceutical compositions in the form of a gel, uses thereof

Publications (1)

Publication Number Publication Date
NO20085158L true NO20085158L (no) 2009-01-15

Family

ID=38895093

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085158A NO20085158L (no) 2006-06-29 2008-12-11 Farmasoytiske blandinger av ropinirol samt deres anvendelse

Country Status (17)

Country Link
US (1) US20080004329A1 (no)
EP (1) EP2032125A2 (no)
JP (1) JP2009542657A (no)
KR (1) KR20090031598A (no)
CN (1) CN101478952A (no)
AR (1) AR063201A1 (no)
AU (1) AU2007269896A1 (no)
BR (1) BRPI0713801A2 (no)
CA (1) CA2654383A1 (no)
IL (1) IL195161A0 (no)
MX (1) MX2008015083A (no)
NO (1) NO20085158L (no)
NZ (1) NZ572481A (no)
PE (1) PE20080374A1 (no)
TW (1) TW200815045A (no)
UY (1) UY30442A1 (no)
WO (1) WO2008005240A2 (no)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212397A1 (en) * 2005-09-15 2007-09-13 Roth Daniel B Pharmaceutical delivery device and method for providing ocular treatment
CA2730787A1 (en) 2008-07-16 2010-01-21 David M. Cohen Topical drug delivery system
PL2391419T3 (pl) 2009-01-29 2019-12-31 Forsight Vision4, Inc. Dostarczanie leku do tylnego odcinka
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CN102361639A (zh) * 2009-04-24 2012-02-22 久光制药株式会社 内包贴附剂的包装袋、及贴附剂的保存方法
SI2462246T1 (en) * 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Fast-setting and / or cessation of substantially unchanged delivery of the product
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
KR20120137373A (ko) 2010-04-30 2012-12-20 테이코쿠 팔마 유에스에이, 인코포레이티드 프로필아미노인단 경피 조성물
SI2600812T1 (sl) 2010-08-05 2021-12-31 ForSight Vision4, Inc., Naprava za zdravljenje očesa
EP3861969A1 (en) 2010-08-05 2021-08-11 ForSight Vision4, Inc. Injector apparatus for drug delivery
WO2012019139A1 (en) 2010-08-05 2012-02-09 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
JP5906302B2 (ja) 2011-03-24 2016-04-20 テイコク ファーマ ユーエスエー インコーポレーテッド 作用剤層および作用剤変換層を含む経皮組成物
US9918945B2 (en) * 2011-05-31 2018-03-20 Hisamitsu Pharmaceutical Co., Inc. Ropinirole-containing patch and package thereof
EP4249059A3 (en) 2011-06-28 2023-11-29 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
SI2755600T1 (sl) 2011-09-16 2021-08-31 Forsight Vision4, Inc. Naprava za izmenjavo tekočine
WO2013070526A1 (en) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
WO2014009241A1 (en) 2012-07-12 2014-01-16 Ferring B.V. Diclofenac formulations
CN104797245B (zh) 2012-11-02 2018-05-04 帝国制药美国公司 丙炔基氨基茚满透皮组合物
WO2014084311A1 (ja) * 2012-11-30 2014-06-05 帝國製薬株式会社 ロピニロール含有貼付剤
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
EP4302736A3 (en) 2013-03-28 2024-04-03 ForSight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
PT2981269T (pt) 2013-04-04 2023-10-10 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
US9463889B2 (en) * 2013-10-25 2016-10-11 Medtronic, Inc. Prefilled reservoir apparatus for ambulatory infusion device
US10258503B2 (en) 2014-07-15 2019-04-16 Forsight Vision4, Inc. Ocular implant delivery device and method
MY182793A (en) 2014-08-08 2021-02-05 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
EP3197429A1 (en) 2014-09-25 2017-08-02 Boehringer Ingelheim Vetmedica GmbH Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
US10500091B2 (en) 2014-11-10 2019-12-10 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
ES2758350T3 (es) * 2015-04-15 2020-05-05 Hisamitsu Pharmaceutical Co Parche transdérmico que contiene ropinirol
CN108430405B (zh) 2015-11-20 2021-04-13 弗赛特影像4股份有限公司 用于缓释药物递送装置的多孔结构
US11617680B2 (en) 2016-04-05 2023-04-04 Forsight Vision4, Inc. Implantable ocular drug delivery devices
CN109922796B (zh) 2016-06-23 2023-04-07 考里安有限责任公司 具有亲水和疏水域的粘合剂基质和治疗剂
KR20230097203A (ko) * 2016-07-27 2023-06-30 코리움, 엘엘씨 도네페질 경피 전달 시스템
WO2019103906A1 (en) 2017-11-21 2019-05-31 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
KR102212722B1 (ko) * 2019-12-23 2021-02-08 환인제약 주식회사 로피니롤을 포함하는 마이크로스피어 및 이를 함유하는 주사제 조성물
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
DE3522550A1 (de) * 1985-06-24 1987-01-02 Klinge Co Chem Pharm Fab Aufspruehbare pharmazeutische zubereitung fuer die topische anwendung
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
GB9511366D0 (en) * 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
AU3474399A (en) * 1998-04-08 1999-10-25 Bracco S.P.A. Pharmacological mri (phmri)
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US20030124176A1 (en) * 1999-12-16 2003-07-03 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
ATE399000T1 (de) * 1999-12-28 2008-07-15 Ajinomoto Kk Antidiabetes-zubereitung zur oralen verabreichung
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
SE0001151D0 (sv) * 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
JP2004500425A (ja) * 2000-04-19 2004-01-08 リリー　アイコス　リミテッド　ライアビリティ　カンパニー パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用
US6770297B1 (en) * 2000-05-26 2004-08-03 Unitech Pharmaceuticals, Inc. Controlled release delivery system of solid dosage form
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2002246490A1 (en) * 2000-10-12 2002-07-30 Pharmacia And Upjohn Company Method of treating parkinson's disease
WO2002036077A2 (en) * 2000-11-06 2002-05-10 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
US6656882B2 (en) * 2001-02-28 2003-12-02 Oms Investments, Inc. Controlled release products and processes for the preparation thereof
NZ528957A (en) * 2001-04-18 2005-05-27 Nostrum Pharmaceuticals Inc A novel coating for a sustained release pharmaceutical composition
US6833478B2 (en) * 2001-07-13 2004-12-21 Sri International N,N-dinitramide salts as solubilizing agents for biologically active agents
DE10137162A1 (de) * 2001-07-30 2003-02-20 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
GB0125088D0 (en) * 2001-10-18 2001-12-12 Smithkline Beecham Cork Ltd New use
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
DE10250711A1 (de) * 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
US20040157910A1 (en) * 2003-02-10 2004-08-12 Smithkline Beecham Corporation Method of treatment or prophylaxis
US7387788B1 (en) * 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
US20070048360A1 (en) * 2005-08-23 2007-03-01 R Carrara Dario N Pharmaceutical compositions with melting point depressant agents and method of making same

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11766418B2 (en) 2016-07-22 2023-09-26 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11826335B2 (en) 2016-07-22 2023-11-28 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11896572B2 (en) 2016-07-22 2024-02-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Also Published As

Publication number Publication date
MX2008015083A (es) 2008-12-10
WO2008005240A3 (en) 2008-05-08
JP2009542657A (ja) 2009-12-03
AR063201A1 (es) 2009-01-14
WO2008005240A2 (en) 2008-01-10
BRPI0713801A2 (pt) 2012-11-06
CA2654383A1 (en) 2008-01-10
UY30442A1 (es) 2008-01-31
NZ572481A (en) 2011-03-31
PE20080374A1 (es) 2008-06-11
AU2007269896A1 (en) 2008-01-10
TW200815045A (en) 2008-04-01
KR20090031598A (ko) 2009-03-26
EP2032125A2 (en) 2009-03-11
US20080004329A1 (en) 2008-01-03
CN101478952A (zh) 2009-07-08
IL195161A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
NO20085158L (no) Farmasoytiske blandinger av ropinirol samt deres anvendelse
EA200800798A1 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
BRPI0416801A (pt) derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
WO2004092146A3 (en) N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
NO20075660L (no) Blanding for behandling av inflammatoriske sykdommer
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
NO20053114L (no) Astma og allergisk inflammasjonsmodulatorer.
ATE372324T1 (de) Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
BRPI0410563B8 (pt) compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas
BRPI0608453A2 (pt) compostos tendo atividade na correção de processamento de cftr mutante e usos destes
NO331211B1 (no) ¿ Beta-2 adrenoreseptor agonister for behandling av bindevevsykdommer i huden¿
BRPI0814958B8 (pt) compostos de indol, e, composição
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
MXPA05011539A (es) Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b.
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
BRPI0507375A (pt) derivados de 1h-tieno[2,3-c]pirazol úteis como inibidores de quinase
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
BRPI0606675A2 (pt) agonista receptor de neuropeptìdio-2, composições farmacêuticas que compreendem o mesmo, compostos, método para o tratamento terapêutico e/ou profilático de enfermidades e utilização dos compostos
RS20050814A (en) Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
WO2006055725A3 (en) Substituted amino acids as protein tyrosine phosphatase inhibitors
BRPI0411863A (pt) derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
BRPI0812494A2 (pt) Derivados de 3',4',5-trimetóxi como estimulante da secreção de muco, método de preparação do mesmo, e composição farmacêutica compreendendo o mesmo

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application